title: Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
abstract: Nonalcoholic fatty liver disease is associated with the metabolic syndrome. The current standard of care, healthy diet and weight loss, has limited effect. The benefits of pharmacological treatments are unclear due to the difficulty of using liver histology as the main outcome in large randomized controlled trials (RCTs). In this issue, an RCT with atorvastatin and antioxidants (vitamins E+C) vs. placebo shows improvement in liver steatosis based on computed tomography scans. The questions are is this beneficial effect due to the combined treatment or the effect of an individual compound; does this intervention improve nonalcoholic steatohepatitis.
authors.forename: Bianca M
authors.initials: BM
authors.lastname: Arendt
authors.forename: Johane P
authors.initials: JP
authors.lastname: Allard
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D000975:Antioxidants / Q000008:administration & dosage; D001205:Ascorbic Acid / Q000008:administration & dosage; D000069059:Atorvastatin; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005234:Fatty Liver / Q000000981:diagnostic imaging / Q000188:drug therapy; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000008:administration & dosage; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D065626:Non-alcoholic Fatty Liver Disease; D016017:Odds Ratio; D011758:Pyrroles / Q000008:administration & dosage; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014801:Vitamin A / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic
chemical_list: D000975:Antioxidants; D001205:Ascorbic Acid; D000069059:Atorvastatin; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014801:Vitamin A